The results displayed—for the first time—that prostaglandin E1 and NDGA are promising CDK2 allosteric inhibitors, which also can be used as leading compounds for designing novel CDK2 allosteric inhibitors and anti-cancer drugs. The gene discussed is CDK2; the disease is cancer.